Modified growth-hormone fragment · Fact sheet

AOD-9604

Also known as AOD9604 · Tyr-hGH 177–191

AOD-9604 is a modified fragment of human growth hormone investigated for fat metabolism. Human safety studies do not establish the fat-loss and joint-repair benefits often associated with it, and it is not FDA approved.

Not FDA approvedLimited or unclear evidence

What is AOD-9604?

AOD-9604 is a short synthetic fragment, not full-length human growth hormone. Its development aimed to separate effects on fat metabolism from other growth-hormone effects.

Benefits & claims

Interest centers on fat loss without the broader effects of growth hormone, and on claims about cartilage or injury recovery. These are separate claims and need separate human outcome evidence.

What the evidence supports

  • Controlled human exposure has been studied; the cited safety analysis reported generally similar tolerability to placebo under study conditions.
  • That finding cannot establish clinical benefit or the safety of different products and routes.
Research areas
  • Obesity
  • Fat metabolism
  • Short-term tolerability

Dosage & frequency

No established human regimen

AOD-9604 is a growth-hormone fragment studied for obesity. Human research has not established an effective approved weight-loss regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • AOD-9604 is not full-length growth hormone and is not the same molecule as every product described as HGH fragment.

Interactions & precautions

  • Human interaction data do not establish compatibility with other hormone or weight-management treatments.

What is still unresolved

  • A reliably effective amount, frequency, route, and long-term safety profile remain unresolved.

Side effects & risks

  • FDA identifies immune-response and impurity concerns and insufficient safety information.
  • The available studies cannot reliably exclude uncommon or long-term harms.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Limited or unclear evidence

A published analysis pools six controlled human studies to discuss tolerability. It is not proof of effective weight reduction or joint repair, and the authors had development-company affiliations.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Appetite: reported experiences

Positive account · personal report

Less hunger alongside tirzepatide

A commenter reported more sustained appetite suppression after adding a product labeled AOD-9604 while already using tirzepatide.

Reported use in this account

Product
Product described as AOD-9604
Amount
250 mcg
Frequency
Every weekday morning
Route
Not specified clearly
Duration
Four weeks

Other exposures described: Tirzepatide, reported at 5 mg weekly

Concurrent tirzepatide prevents attribution to AOD-9604. The account does not verify product identity or establish an independent weight-loss effect.

Read the appetite account

Approval status

AOD-9604 has no FDA-approved therapeutic product. FDA compounding committee consideration is a separate process and does not authorize weight-loss or recovery claims.

No FDA-approved product

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Durable, meaningful weight-loss benefit
  • Human joint-repair outcomes
  • Safety across formulations and routes

Summary

AOD-9604 has human research history, but the evidence reviewed here does not establish it as a weight-loss or recovery treatment.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety concerns for selected bulk substances

    Ingredient-specific safety findings; compounding review is not drug approval.

  2. journalAOD-9604 human safety and tolerability analysis

    Pooled safety analysis of six controlled trials; development-company conflicts and route limits matter.

  3. fdaFDA advisory committee: AOD-9604 review

    December 2024 meeting summary documenting consideration of AOD-9604 for the compounding bulks list.

How we assess sources · Suggest a correction